Safety and efficacy of amplatzer duct occluder for percutaneous closure of ventricular septal defects with tunnel shape aneurysm: Medium term follow up

Objectives: Different devices including Amplatzer duct occluder has been used for percutaneous closure of ventricular septal defects. This study reports our medium term follow up of perimembranous and muscular ventricular septal defects with tunnel shape aneurysm closure using the Amplatzer duct occluder. Materials and Methods: From May 2006-December 2012, we used Amplatzer duct occluder in seven ventricular septal defect patients here atHamad General Hospital,Doha,Qatar. There were 4 male and 3 female patients with an age range of 4 - 32 years with a median of 8 years and weight range of 16 - 63 kgwith a median of33 kg. In this group, 6 were perimembranous and 1 muscular and all these ventricular septal defects had a tunnel shape aneurysm. Transesophageal echocardiographic diameter ranged from 4 - 8 mmand Qp/Qs was 1 - 1.6. Angiographically, the diameter on the left ventricular side measured 3.5 - 10 mmand on right ventricular side 2.4?- 5 mm. 8/6 mmAmplatzer duct occluder was used to close these ventricular septal defects. Results: There were no major complications and immediately after the procedure there was no residual shunt in any of these patients and all the patients remained in normal sinus rhythm. One patient was expatriate and no further follow up was available. The rest of the 6 patients had 1 - 80 months with a median of 54 months follow up and none of these patients had any residual shunt and all remained in normal sinus rhythm. Two patients developed trivial aortic valve regurgitation immediate post procedure, one remained unchanged and the 2nd has progressed to mild at this latest follow up. Conclusion: Amplatzer duct occluder is feasible and a safe device for percutaneous closure of selective tunnel shape aneurysmal perimembranous and muscular ventricular septal defects.

Transcatheter Closure of Perimembranous Ventricular Septal Defect Using the Amplatzer Duct Occluder II

Objective:To evaluate the efficacy of Amplatzer duct occluder II(ADO II)in the treatment of perimembranous ventricular septal defect(pmVSD)in children.Methods:Between June 2017 and June 2020,13 patients with pmVSD had attempted transcatheter closure using ADO II,seven of patients were used antegrade approach and six of them were used retrograde approach.Results:There were 8 males and 5 females,age from 1 to 7 years,weight from 10.5 to 31.0 kg,and VSD size from 2.0 to 4.0 mm.Procedure was successful in all cases with the outer diameter of the occluders ranging from 4 to 6 mm.No aortic,tricuspid regurgitation or residual shunt was found in the immediate ultrasound assessment.No arrhythmia was observed in the Holter monitoring 3 days after the intervention.Discharge echocardiography indicated complete shunt closure.No evidence of occluder prolapse,malignant arrhythmia,or intensed valve regurgitation was seen on a median follow-up of 18 months(range,6 to 36 months).Conclusions:Based on our experience,ADO II showed good efficacy in the early and middle stages of pediatric pmVSD closures.

Effectiveness and Safety of Transcatheter Closure of Various Ventricular Septal Defects Using Second-Generation Amplatzer Duct Occluders

Objective:This study was designed to determine the long-term safety and efficacy of using the Amplatzer Duct Occluder II(ADO II)for the closure of various ventricular septal defects(VSDs).Methods:From January 2011 to December 2019,selected VSD patients were treated through transcatheter intervention using ADO II occluders.The closure results and complications from 188 patients,involving 167 perimembranous ventricular septal defects(pmVSDs),9 intracristal VSDs,11 post surgery residual shunts and 1 post closure residual shunt with the mean outlet diameter3.1±0.8 mm under angiography,were enrolled in this study.Results:The success rate was 98.9%for all procedures.During the median 77-month follow-up period,no cases of complete atrioventricular block(cAVB),infective endocarditis or death occurred.One major adverse event(0.5%)was recorded:cerebrovascular accident occurred 1 day after the procedure in one patient who was transferred to the neurology department.The residual shunt rate was 44.6%,which was the most common minor adverse event.The cardiac conduction block rate was 4.3%.Specifically,one pmVSD patient developed intermittent LBBB during the 28-month follow-up.There were 3 patients(1.6%)with new-onset mild tricuspid insufficiency,and the insufficiency degree was stable during follow-up.There was no new-onset aortic insufficiency that occurred.Conclusions:Transcatheter closure of pmVSDs,some intracristal VSDs,some postsurgery or postclosure residual shunts using ADO II occluders were both safe and effective and yielded excellent long-term results in selected patients.

Clinical Study on Amplatzer Occluder Device to CloseVentricular Septal Defect

Objectives To evaluate the therapeutic effect of transcatheter Amplatzer device on the closure of ventricular septal defect （VSD）. Methods Among 143 patients with VSD, 135 patients with perimembrane VSD and 2 with muscular VSD aged 2.5 -28 years old, were successfully closed with Amplatzer oeeluder device by the pereutaneous guidwire through femoral artery-VSD-femoral vein route under the guidance of fluoroscopy, ventrieulography and transthoracic echocardiography （TIE）. The diameters of the VSDs were 2.3-15.7 （6.90±2.76）mm by left ventriculography. Results The success rate of transcatheter closure of VSD with Amplatzer devices was 96%（137/143）. Minimal residual amount of shunts were found in one patient, although the shunts was decreased one month after the procedure. There were one patient who had respiratory arrest during the procedure, 7 patients（5%）had conduction disturbance, 3 patients had complete left bundle branch block, 2 patients had complete right bundle branch block, 1 patient had Ⅰ degree atrial-ventricular block and 1 patient had Ⅲ degree atr/al-ventricular block during hospitalization. The diameters of the occluder ranged from 4 to 23 （9.13±3.31）mm and were symmetrical in 122 patients and asymmetrical in 15 patients. Conclusions Transcatheter closure of the perimembranous ventrieular septal defect using Amplatzer VSD occluder device is an efficient method for patients with the perimembranous VSD. The operation is simple with a high success rate and a good effect.

Safety of an improved patent ductus arteriosus occluder for transcatheter closure of perimembranous ventricular septal defects with abnormally attached tricuspid chordae tendineae

BACKGROUND The off-label use of various devices has been reported for the transcatheter closure of perimembranous ventricular septal defects(PmVSD) because of serious complications, such as heart block and tricuspid regurgitation(TR),associated with conventional ventricular septal defect devices. However, whether certain defects such as PmVSD with abnormally attached tricuspid are fit for interventional treatment is still disputable.AIM To explore the feasibility and safety of transcatheter closure of PmVSD with abnormally attached tricuspid chordae tendineae using an improved patent ductus arteriosus(PDA) occluder.METHODS We retrospectively analyzed 20 patients diagnosed with PmVSD with abnormally attached tricuspid chordae tendineae who underwent interventional treatment using an improved PDA occluder at our center from January 2012 to January 2016. Baseline characteristics and procedural and follow-up data were analyzed.RESULTS All 20 patients achieved procedure success. No heart block occurred during the operation. One patient had a transient complete right bundle branch block within48 h post-procedure and reverted to normal rhythm after intravenous injections of dexamethasone for 3 d. For all 20 patients, no residual shunt was observed by transthoracic echocardiography post-procedure. During the average follow-up period of 2.4 years, no severe TR was observed.CONCLUSION Using of the improved PDA occluder for the transcatheter closure of PmVSD with abnormally attached tricuspid chordae tendineae is a safe and promising treatment option. However, long-term follow-up in a large group of patients is still warranted.

Transcatheter Closure of a Right Pulmonary Artery to Left Atrium Fistula Using a Ventricular Septal Defect Occluder

Background:Communication between the right pulmonary artery(RPA)and left atrium(LA)is a rare cause of central cyanosis in pediatric patients.Case presentation:We describe a 3-year-old female patient with an oxygen saturation of 70%at admission.The echocardiogram indicated an abnormal color flow Doppler in the LA and she underwent standard cardiac catheterization.The angiography of pulmonary artery revealed a 7.4 mm×7.6 mm fistula between the RPA and LA and achieved successful closure using ventricular septal defect occlusion.Conclusion:The fistula between pulmonary artery and left atrium is an extremely rare but treatable congenital defect.It should be considered in differential diagnosis of cyanosis in children.

TRANSCATHETER CLOSURE OF LARGE SECUNDUM ATRIAL SEPTAL DEFECTS WITH AMPLATZER~ SEPTAL OCCLUDER

Objective To evaluate the safety and feasibility of transcatheter closure of large secundum atrial septal defects(ASDs)with Amplatzer~ septal occluder(ASO).Methods A total of 26 patients(age 16 to 67 years,median 43 years;body weight 52 to 102 kg,median 67 kg)with large ASDs underwent an attempted transcatheter closure using ASO.Large ASD was defined as those with a balloon-stretched diameter of ≥30 mm.Another 81 patients with small-to-moderate ASD during same period who underwent closure served as controls.Results In patients with large ASDs,the ASD dimension means were(22.1±3.2)mm(range from 16 to 30 mm)and(23.8±2.6)mm(range from 18 to 31mm)assessed by transesophageal echocardiography(TEE)and transthoracic echocardiography(TTE),respectively.The mean balloon-stretched diameter of the ASD was(31.9±2.1)mm(range from 30 to 37mm).The size of device was(32.0±1.9)mm(range from 30 to 36mm).The transcatheter procedure was successful in all patients(100%).Seventeen deployments were performed using the conventional left atrium approach,and remaining 9 patients required the right upper pulmonary vein approach.Immediately after deployment,TEE revealed that complete closure rate was 73%.Procedure-related complications were recorded in 3 patients(12%),including device embolization in one patient,pericardial effusion in one patient,and large hematoma at puncture site in one patient.During follow-up,the complete closure rate increased to 88% at 24h after procedure and 100% at 6 months.The procedural success rates,immediate TEE results and TTE results at 24h and 6 months after procedure,were not significantly different between patients with large ASDs and those with small-to-moderate ASDs.Conclusion Transcatheter closure of large ASDs using ASO is technical feasible and relatively safe.Proper care selection and specific technique modification such as the right upper pulmonary vein approach is vital for the implantation success.

Cardiac resynchronization therapy for heart failure induced by left bundle branch block after transcatheter closure of ventricular septal defect

A 54-year-old female patient with congenital heart disease had a persistent complete left bundle branch block three months after closure by an Amplatzer ventricular septal defect occluder. Nine months later, the patient suffered from chest distress, palpitation, and sweating at daily activities, and her 6-min walk distance decreased significantly （155 m）. Her echocardiography showed increased left ventricular end-diastolic diameter with left ventricular ejection fraction of 37%. Her symptoms reduced significantly one week after received cardiac resynchronization therapy. She had no symptoms at daily activities, and her echo showed left ventricular ejection fraction of 46%and 53%. Moreover, left ventricular end-diastolic diameter decreased 6 and 10 months after cardiac resynchronization therapy, and 6-min walk dis-tance remarkably increased. This case demonstrated that persistent complete left bundle branch block for nine months after transcatheter closure with ventricular septal defect Amplatzer occluder could lead to left ventricular enlargement and a significant decrease in left ventricular systolic function. Cardiac resynchronization therapy decreased left ventricular end-diastolic diameter and increased left ventricular ejection fraction, thereby improving the patient’s heart functions.

Amplatzer动脉导管封堵器-Ⅱ治疗伴发主动脉窦脱垂室间隔缺损患儿效果分析

目的探讨Amplatzer动脉导管封堵器(ADO)-Ⅱ治疗伴发主动脉窦脱垂室间隔缺损(VSD)患儿的效果。方法回顾性收集2018年1月至2022年9月于湖南省儿童医院住院治疗的94例伴发主动脉窦脱垂VSD患儿临床资料。其中男60例,女34例,年龄为(4.7±3.1)岁;主动脉窦轻中度脱垂83例,VSD为(4.12±0.97)mm,重度脱垂11例,VSD为(4.95±0.51)mm;VSD类型为膜周部54例,嵴内以上40例。分析VSD大小、主动脉窦脱垂程度与ADO-Ⅱ选择的关系,以及术后中期主动脉瓣反流、残余漏变化,明确ADO-Ⅱ对此类患儿的适用性。结果术后中期最终存留主动脉瓣轻度反流6例,多发于使用4-4 mm、5-4 mm型ADO-Ⅱ封堵器;残余漏10例,主要发生于使用5-4 mm、6-4 mm型封堵器。结论ADO-Ⅱ封堵器在置入形态良好状况下,适用于VSD<6 mm伴主动脉窦脱垂患儿。术后有一定的残余漏和主动脉脉瓣反流发生,但能满足介入治疗要求。

用Amplatzer导管封堵器介入闭合先天性膜周部室间隔缺损

目的 研究Amplatzer导管封堵器 (ADO)介入闭合先天性膜周部室间隔缺损 (VSD)的可行性、安全性和有效性 ,确定其适应证和并发症。方法 2 0 0 1年 5月至 2 0 0 2年 1 2月 ,经导管闭合先天性膜周部VSD 4 1例 ,VSD直径 4～ 1 2 .8(平均 6 .0 )mm ,其上缘距离主动脉右冠瓣 4 .5～ 1 2 (平均 6 .6 )mm。心导管资料示QP/QS 1 .4～ 2 .6 (平均 1 .7) ,肺动脉收缩压 1 9～ 34(平均 2 5 )mmHg。 4 1例膜周部VSD中 ,1 8例伴有膜部膨出瘤。结果 4 1例VSD均顺利闭合成功 ,选用的ADO尺寸为 6 / 4～ 1 6 /1 4mm。术后心脏杂音立即消失 ,选择性左心室造影及经胸超声心动图均无明显残余分流。胸片示肺血管影较术前减少。心电图有 1 2例出现不完全性右束支传导阻滞 ,1例出现完全性左束支传导阻滞 ,均在 1～ 2周内自行消失。随访 2～ 2 1个月 ,临床及实验室资料进一步改善 ,未见ADO移位、主动脉瓣或三尖瓣返流及其他并发症。结论 用ADO介入闭合先天性膜周部VSD是完全可行的 ,而且具有操作简便、安全高效。

术中应用Amplatzer封堵器关闭婴儿多发性肌部室间隔缺损

目的报道1例小婴儿肌部多发性室间隔缺损(VSD)术中镶嵌治疗的初步经验。方法正中胸骨切口开胸,在食管超声的导引下,在跳动心脏的右心室表面导入Amplatzer封堵器关闭2处肌部VSD。结果成功封堵2处肌部VSD,术后恢复顺利。结论将手术和介入治疗结合的镶嵌治疗小婴儿肌部VSD是一种安全、有效的方法。

Amplatzer封堵器介入治疗房间隔缺损及动脉导管未闭的疗效评价

目的 评价用Amplatzer封堵器治疗房间隔缺损 (ASD)及动脉导管未闭 (PDA)的疗效与安全性。方法 5 0例(男 2 3例、女 2 7例 ,年龄 3～ 64岁 )中ASD 19例、PDA 3 1例 ,按常规在局麻或全麻下完成心导管检查及造影。ASD封堵时先用测量球囊测ASD直径及选取Amplatzer封堵器 ,经传送装置将封堵器推送至左房 ,先后释放左、右侧盘 ,心脏超声证实ASD封堵完全、无残余分流、不影响二尖瓣活动时 ,再将Amplatzer封堵器完全释放。PDA患者先行主动脉弓降部侧位造影 ,测量PDA直径及选择Amplatzer蘑菇伞封堵器 ,经传送装置将封堵器置于未闭的动脉导管内 ,重复主动脉造影证实无残余分流时释放封堵器。结果 ① 19例ASD患者球囊测得的ASD直径为 2 3± 6( 13～ 3 1)mm ,所用封堵器直径为 17～ 40mm ,均一次性封堵成功。② 3 1例PDA患者中 3 0例用Amplatzer蘑菇伞封堵成功 ,1例PDA内径达 12mm者用直径 17mm的Amplatzer房间隔封堵器封堵成功。无并发症发生。结论 用Amplatzer封堵器治疗ASD及PDA具有操作简便、疗效肯定、创伤小、适应症广及并发症少的特点 。

应用Amplatzer偏心性封堵器介入治疗膜部室间隔缺损

目的 应用Amplatzer偏心性封堵器治疗膜部室间隔缺损 (perimembraneventicularseptaldefect,PMVSD)并对近期疗效进行观察。方法 6例PMVSD患者均经胸超声心动图确诊 ,术中经左心室造影明确缺损直径为 3～ 9mm ,平均 5 5mm ;经左心系统、室间隔缺损处、右心系统建立导丝轨迹 ,沿导丝经传送鞘管送直径 6～ 12mm(平均 8mm)的Amplatzer封堵器至缺损处行封堵 ;术后 2 4h、1月、3月分别行经胸超声及X线检查观察临床疗效。结果 全组技术成功率 10 0 % ,术中未发生任何重要并发症。全部患者封堵后无一例存在残余分流 ,术后即刻完全封堵率 10 0 % ;术后 2 4h、1月及 3月经胸超声心动图检查无残余分流 ,X线检查全部显示肺血减少 ,心胸比例不同程度缩小。 1例患者术后出现完全性左束支传导阻滞 ,1月随访时消失。结论 经导管置入Amplatzer偏心性膜部室间隔缺损封堵器治疗PMVSD是一种成功率高、近期疗效可靠的介入方法 ,其远期疗效需进一步观察。

继发孔房间隔缺损的Amplatzer封闭器介入外科手术治疗的对比研究(英文)

目的 对继发孔房间隔缺损 (ASDⅡ )的Amplatzer间隔封闭器 (ASO)介入和外科治疗的疗效和安全性进行比较研究。方法 1998年 5月～ 2 0 0 2年 12月接受ASO治疗的 72例和接受外科手术治疗的 6 6例ASDⅡ病人进行对比研究。结果 ASO组和外科组技术成功率分别为 97.2 % (70 /72例 )和 10 0 % ;ASO组的手术和住院时间明显短于外科组 (71.8± 11.6 )min和 (15 8.4± 31.8)min ;(8.8± 2 .3)d和 (2 6 .9± 9.9)d ,(P<0 .0 5 ) ;ASO组的手术并发症发生率明显低于外科组 (7.1%和 2 2 .7% ,P <0 .0 5 ) ;ASO组无病人接受输血 ,外科组接受输血率 89.1% (5 9/6 6例 ) ;ASO组费用明显高于外科组 (4 .4 5± 0 .5 3)万元和 (1.87± 0 .5 4 )万元 ,(P <0 .0 5 )。结论 继发孔ASD的ASO治疗在有适应症的范围内可替代外科手术 ,降低ASO费用有助于更广泛推广作用。

成人继发孔房间隔缺损的Amplatzer间隔封闭器介入治疗

目的:探讨成人继发孔房间隔缺损(ASD Ⅱ)的Amplatzer间隔封闭器(ASO)介入治疗的疗效和安全性。方法:对接受ASO治疗的49例成人ASDⅡ患者的疗效、安全性进行研究。结果:全组患者技术成功率为95.6％(47/49例);ASDⅡ平均大小(28.2±5.3)mm,ASO平均大小(31.1±6.5)mm;术前平均肺动脉收缩压(39.3±13.4)mmHg(1 mmHg=0.133 kPa),肺动脉血流量/主动脉血流量(Qp/Qs)平均为2.4±1.1,ASD的成功封闭率即刻为91.5％(43/47例),术后24 h为100％;手术并发症发生率4.3％(2/47例);平均随访(11.7±3.6)个月,无ASO移位或破损。结论:成人ASD Ⅱ的ASO治疗疗效和安全性均好,在有适应证的范围内可替代外科手术。

第二代Amplatzer动脉导管未闭封堵器经股动脉逆行插管行室间隔缺损封堵术疗效评价

目的探讨第2代Amplatzer动脉导管未闭封堵器（ADOⅡ）经股动脉逆行插管行室间隔缺损封堵术疗效。方法室间隔缺损患者5例,年龄5-53岁,经胸超声心动图显示室间隔缺损为4-6mm。第二代Amplatzer动脉导管未闭封堵器经股动脉逆行插管行室间隔缺损封堵术,术后24小时、6个月及1年行超声心动图、X线平片及心电图进行随访。结果造影显示室间隔缺损3-5mm,肺动脉压为14-28mmHg（1mmHg=0.133kPa）。5例封堵器植入均获得成功,术后即刻2例存在微量残余分流,术后24小时5例室间隔缺损均完全闭合。随访中未见室间隔缺损再通及其他并发症。结论对于部分有选择的病例,应用ADOⅡ经股动脉逆行插管行室间隔缺损封堵术安全可行,可简化操作流程。

Amplatzer封堵器经导管治疗多孔房间隔缺损

目的 :探讨 Amplatzer封堵器经导管治疗多孔房间隔缺损的临床应用价值。方法 :全组患者 6(男 2 ,女 4)例 ,年龄 4～ 5 0岁 ,经 TTE或 TEE检查诊断为多孔房间隔缺损。均在 X线和 TTE或 TEE监测下经导管行 Amplatzer封堵器治疗。术后重复 TTE或 TEE、ECG及 X线平片检查以评价疗效。结果 :全组 6例患者 Amplatzer封堵器置入均获成功 ,术中无重要并发症发生。其中置入 1个封堵器的患者 5例 ,置入 2个封堵器的患者 1例。术后即刻TTE或 TEE检查 5例无残余分流 ,1例小缺损孔有少量残余分流 ,随访 1年中少量残余分流仍存在。1例肺动脉压中度增高患者 ,术后 3 0 min测量肺动脉压下降 >2 0 mm Hg。随访期间所有患者封堵器位置形态良好 ,未发现封堵器的变形 ,移位以及金属结构断裂等改变 ;右房 ,右室有不同程度的缩小 ,X线平片显示肺血有不同程度减少 ;术后ECG检查均未见心律失常发生。结论 :Amplatzer封堵器经导管治疗多孔房间隔缺损是安全有效的。对于相隔距离较近的多孔房间隔缺损 ,可采用单个封堵器封堵 ;而相隔距离较远的缺损 。

经胸超声心动图引导Amplatzer封堵器经心导管封堵房间隔缺损及疗效观察

目的探讨经胸超声心动图(TTE)在引导Amplatzer封堵器经心导管封堵继发孔型房间隔缺损中的作用,并评价其初步疗效。方法运用TTE选择出适于封堵术的继发孔型ASD患者36例,并配合X线指导封堵过程,选择合适型号的封堵器并观察随访疗效。结果TTE引导封堵技术成功率100%。术后封堵完全闭合率91.7%(33/36),1个月为94.4%(34/36),3个月以上为100%。TTE所测房缺的最大直径明显小于球囊伸展径(P<0.01),但二者高度相关(r=0.93),为封堵器型号的选择提供了依据。本组36例术后随访,均未发现封堵器结构断裂、移位、血栓形成等并发症发生。结论运用TTE引导Amplatzer封堵器经心导管封堵继发孔房缺是一种安全、有效的非外科手术方法,近中期疗效可靠。较之经食管超声运用范围更广,操作更简便、安全,更易掌握及推广。

Amplatzer房间隔封堵器治疗200例的并发症

目的 :总结我院连续 2 0 0例房间隔缺损采用 Amplatzer封堵器治疗的并发症。方法 :接受治疗的患者 2 0 0 (男68,女 13 2 )例 ,年龄 2 6± 16(1.0～ 67)岁 ,均经症状、体征、X线、ECG、B超等确诊为房间隔缺损 ,并发肺动脉瓣狭窄5例 ,二尖瓣狭窄 2例 ,动脉导管未闭 2例 ,多孔房间隔缺损 10例。所有患者在我院行 Amplatzer房间隔缺损封堵治疗 ,同时观察术中、术后出现的并发症。结果 :房间隔缺损大小为 2 0± 8(2 .5～ 3 7) mm,植入的封堵器大小为 2 6±9(5～ 40 ) mm,共植入 Amplatzer房间隔封堵器 2 0 3个 ,技术成功率 99.5% ,同时植入 2个封堵器的患者共 4例。严重并发症发生率为 2 % (4例 ) ,1例术后心包填塞急诊转到心脏外科手术 ;1例术后 2 d出现不明原因的脑出血 ;1例术中导管断裂 ,急诊转心脏外科手术取出断裂导管并行修补术 ;1例术后 3月、6月出现封堵器内少至中量分流。其他并发症有术中出现 ST段弓背向上抬高 8例 ,暂时性 度 型及 度 型房室传导阻滞各 2例 ,术后发生房颤4例。结论 :Amplatzer封堵器治疗房间隔缺损严重并发症发生率低 ,作者认为是一种安全。

经导管Amplatzer双面伞堵闭器关闭继发孔房间隔缺损

目的观察Amplatzer双面伞堵闭器关闭继发孔房间隔缺损(ASDⅡ)的临床疗效及安全性.方法超声心动图及临床诊断为ASDⅡ病人30例,选择经导管Amplatzer双面伞房间隔缺损关闭治疗.结果超声测定ASDⅡ直径为13～25mm,ASDⅡ最大伸展径及所选Amplatzer房间隔堵闭器为18～38mm.成功率为100%,超声心动图示术后即刻、24小时后及3个月后残余分流分别为40%、9.9%和3.3%.手术中除一过性房性心动过速和房室传导阻滞外,无其他并发症.3个月随访,所有病人临床症状及心脏大小改善,未发现并发症.结论 Amplatzer双面伞房间隔堵闭器关闭ASDⅡ临床疗效及安全性均好.